EUROPEAN shares closed higher on Monday as a soft business activity reading strengthened the case for more monetary policy ...

Shares of Skye Bioscience gained after the San Diego biopharmaceutical company highlighted the safety of its in-development obesity treatment as compared with rivals. AstraZeneca shares slipped after ...

Analysis of the TROPION-Breast01 study showed that treatment with Dato-DXd did not significantly improve overall survival compared with chemotherapy in HR-positive, HER2-low or -negative breast cancer ...

The experimental precision drug, developed with Japan's Daiichi Sankyo, did not significantly improve overall survival rates ...

Despite showing a progression-free survival benefit, the antibody-drug conjugate did not improve overall survival in HR-positive, HER2-negative or -low breast cancer.

AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly ...

A cancer drug being developed by AstraZeneca failed to "achieve statistical significance" in helping patients live longer ...

AstraZeneca released results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan, showing no statistically ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...

AstraZeneca plc (AZN, AZN.L) announced on Monday that the high-level results from the TROPION-Breast01 Phase III trial of datopotamab ...

(Alliance News) - AstraZeneca PLC on Monday said a breast cancer drug failed to significantly extend patients' lives, a second blow this month to hopes for the product. Datopotamab deruxtecan, also ...